MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2019 International Congress

    Quantitative Motor (Q-Motor) Assessments Suggest a Beneficial Central Effect of Laquinimod in a Phase II Study in Huntington Disease (LEGATO-HD)

    R. Reilmann, M. Gordon, R. Schubert, K. Anderson, A. Feigin, S. Tabrizi, B. Leavitt, J. Stout, P. Piccini, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Muenster, Germany)

    Objective: Evaluate the change from baseline at week 52 in Q-Motor (Quantitative Motor) measures, exploratory, standardized, and rater-independent outcomes in the LEGATO-HD study. Background: LEGATO-HD…
  • 2019 International Congress

    Sustained mutant huntingtin lowering in the brain and cerebrospinal fluid of Huntington disease minipigs mediated by AAV5-miHTT gene therapy

    A. Vallès-Sanchez, A. Stam, C. Brouwers, J. Klíma, B. Bohuslavová, R. Pintauro, M. Sogorb-Gonzalez, L. Paerels, V. Fodale, A. Bresciani, Z. Ellederová, B. Blits, J. Motlik, S. van Deventer, M. Evers, P. Konstantinova (Amsterdam, Netherlands)

    Objective: To assess the translatability and long-term efficacy of gene therapy-mediated huntingtin (HTT)-lowering in a large animal model of Huntington disease (HD), transgenic HD (tgHD)…
  • 2019 International Congress

    Path to Prevention (P2P) – Developing a Prodromal PD Progression Biomarker Program

    K. Marek, A. Siderowf, C. Coffey, T. Foroud, V. Arnedo, E. Flagg, S. Chowdhury, K. Kieburtz, L. Chahine, J. Seibyl (New Haven, CT, USA)

    Objective: The overall objective of the Path to Prevention (P2P) initiative is to identify clinical, imaging, and biologic markers of progression during the prodromal phase…
  • 2018 International Congress

    A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease

    H. Huttunen, S. Booms, J. Koskinen, M. Saarma (Espoo, Finland)

    Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…
  • 2018 International Congress

    Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy

    P. Howson, T. Johnston, J. Brotchie, M. Hill, J. Koprich (Toronto, ON, Canada)

    Objective: We evaluated the efficacy of JNX3001 in an aSyn-based macaque model with plasma exposures associated with efficacy in rodents. Background: Alpha-synuclein (aSyn) deposition is…
  • 2018 International Congress

    Motivators, Barriers and Clinical Correlates of Physical Activity in Parkinson Disease

    S. Mantri, S. Wood, J. Duda, J. Morley (Philadelphia, PA, USA)

    Objective: To characterize physical activity levels as well as barriers and motivators for exercise in US military Veterans with Parkinson disease (PD). Background: Physical activity…
  • 2018 International Congress

    Nurr1 gene: A new research target for Parkinson’s disease

    W. Le (Dalian, China)

    Objective: The objective of our study is to determine if Nurr1 gene, a transcription factor essential for dopamine (DA) neuron development and survival, is a…
  • 2018 International Congress

    T lymphocytes in Parkinson’s disease pathogenesis and therapy: A systematic review

    J. Baird, J. Quinn (Portland, OR, USA)

    Objective: A systematic literature review was conducted to synthesize the current state of knowledge on the role of T lymphocytes in Parkinson’s disease (PD) pathology…
  • 2018 International Congress

    Activation of chaperone-mediated autophagy reduces oligomeric alpha-synuclein accumulation in LRRK2(R1441G) knockin mouse model of Parkinson’s disease (PD)

    P.W.L. Ho, C.S.C. Lam, M.C.T. Leung, S.Y.Y. Pang, H.F. Liu, L. Li, M.H.W. Kung, D. Ramsden, SL. Ho (Hong Kong)

    Objective: To determine age-dependent accumulation of oligomeric alpha-synuclein in the brain of aged LRRK2(R1441G) knockin mice; and to explore whether activation of chaperone-mediated autophagy (CMA)…
  • 2018 International Congress

    Enhancing protein palmitoylation is protective in alpha-synuclein dependent cytotoxicity

    G. Ho, T. Imberdis, S. Nuber, U. Dettmer, D. Selkoe (Boston, MA, USA)

    Objective: To determine if enhancement of protein palmitoylation benefits alpha-synuclein (aS) dependent vesicular trafficking defects and cytotoxicity. Background: Recent studies suggest that vesicular trafficking defects…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 22
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley